Chronic kidney disease (CKD) screening in individuals with type 2 diabetes is essential to prevent progression to end-stage renal disease (ESRD). Patients with diabetes are at an increased risk of CKD, yet a significant proportion remain undiagnosed. Early detection is critical, as it allows for timely intervention to slow disease progression.1 Screening typically involves measuring urinary albumin excretion (UAE), which helps identify early signs of kidney damage. Regular monitoring of UAE and estimated glomerular filtration rate (eGFR) can aid in the early identification of CKD.2 Screening should begin at diagnosis in patients with type 2 diabetes and continue annually, as early intervention with lifestyle changes and pharmacologic treatments, such as ACE inhibitors or ARBs, can significantly reduce the risk of ESRD and improve long-term outcomes.